{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:46:21Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 18.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09501-a63f-79c0-84db-0b48131b4cfd\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: flunisolide\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 73.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09501-a63e-7ed1-b6bd-9ed23218c974\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: flunisolide\nRegistry id: vr.tr.flunisolide\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:57:40+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q3746835", "registryId": "vr.tr.flunisolide", "name": "flunisolide", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q3746835/", "model": { "registry_id": "vr.tr.flunisolide", "name": "flunisolide", "purpose": "Enable an agent to recognise flunisolide, assess the identity and condition of a material lot, and determine its suitability for a specified research or pharmaceutical use.", "definition": "Flunisolide is a synthetic fluorinated glucocorticoid used as a locally administered anti-inflammatory drug in inhaled preparations for asthma maintenance and intranasal preparations for allergic rhinitis.", "scope_statement": "This model owns flunisolide as the chemical substance registered as vr.tr.flunisolide in PHY / PHY.MAT, including molecular identity, material form, quality, stability and use constraints; it links to finished medicines without treating them as the substance itself.", "in_scope": [ "Molecular structure, stereochemistry and verified substance identifiers", "Anhydrous, hydrated or solvated material descriptions within the registry entry", "Lot composition, assay basis, impurities and pharmaceutical or research grade", "Physical properties, dissolution behaviour and storage-dependent condition", "Evidence linking substance quality and hazards to an intended use" ], "out_of_scope": [ "Finished nasal solutions and inhalation products, including excipients and labelled strength", "Spray pumps, inhalers and delivered-dose performance", "Patient diagnosis, prescribing and individual treatment decisions", "Manufacturing processes and production equipment", "Other corticosteroids and flunisolide metabolites as independent substances" ], "distinguishing_features": [ "Require agreement with the reference flunisolide stereostructure, including its 6α-fluoro substitution and cyclic 16,17-acetal with acetone; a corticosteroid class label alone is insufficient.", "Use C24H31FO6 and approximately 434.51 g/mol as consistency checks for the unsolvated molecule, while requiring structural evidence to distinguish isomers. [DailyMed substance description](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f39cae46-c68f-47ef-82f3-4fd3dd46c74c)", "Distinguish neat flunisolide from a solution containing flunisolide by recording the full composition and the denominator used for concentration.", "Distinguish water or solvent associated with the material from the parent molecular identity before interpreting molecular mass, assay or weighed quantity.", "Match identifiers to a stereochemically specified substance record rather than accepting a similarly named supplier or product record; PubChem lists flunisolide as CID 82153. [PubChem flunisolide](https://pubchem.ncbi.nlm.nih.gov/compound/Flunisolide)" ], "characteristics": [ { "name": "Reference molecular identity", "kind": "relation", "unit_or_values": "Verified stereostructure, structure identifier and registry cross-references", "why_it_matters": "Prevents substitution of another corticosteroid, isomer or incompletely specified chemical record." }, { "name": "Molecular formula and molar mass", "kind": "measurement", "unit_or_values": "C24H31FO6; approximately 434.51 g/mol for the unsolvated molecule", "why_it_matters": "Supports identity checks and mass-to-amount calculations when the material basis is established." }, { "name": "Material form", "kind": "category", "unit_or_values": "Anhydrous, hydrate, solvate or unresolved; crystalline form where established", "why_it_matters": "Associated water or solvent can alter assay interpretation and material performance." }, { "name": "Flunisolide assay", "kind": "measurement", "unit_or_values": "% m/m with as-is, dried or anhydrous basis and analytical method", "why_it_matters": "Determines the amount of flunisolide present without equating chromatographic area purity with mass fraction." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Individual and total related substances, residual solvents and other specified contaminants in % or ppm", "why_it_matters": "Establishes whether a lot meets the specification required for its intended use." }, { "name": "Water content", "kind": "measurement", "unit_or_values": "% m/m with method and sampling conditions", "why_it_matters": "Supports mass-basis correction and investigation of hydration or storage changes." }, { "name": "Solubility", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with solvent composition, temperature, equilibration and solid form", "why_it_matters": "Supports solvent selection and precipitation assessment; qualitative descriptions alone cannot determine a workable formulation." }, { "name": "Thermal behaviour", "kind": "measurement", "unit_or_values": "°C with method and identification of melting, desolvation or decomposition", "why_it_matters": "Allows thermal observations to be interpreted without assuming every transition is a melting point." }, { "name": "Lot disposition", "kind": "state", "unit_or_values": "Quarantined, released for a named use, rejected or awaiting retest", "why_it_matters": "Separates chemical identity from permission to use a particular lot." }, { "name": "Applicable handling evidence", "kind": "relation", "unit_or_values": "Material-specific safety data sheet, exposure assessment and dated jurisdictional requirements", "why_it_matters": "Prevents a finished-product safety record from being applied automatically to concentrated flunisolide powder." } ], "affordances": [ "Resolve a flunisolide label or identifier against a verified stereostructure.", "Compare a lot certificate and analytical results with a named use specification.", "Calculate flunisolide-equivalent quantities using verified assay and water or solvent basis.", "Select candidate dissolution conditions from measured solubility evidence.", "Flag identity mismatches, degradation evidence or insufficient documentation for quarantine.", "Link a qualified substance lot to a formulation model while preserving substance and product boundaries." ], "agent_conduct": { "may": [ "Identify flunisolide by name, identifiers and documented properties, citing sources.", "Report approved inhaled and nasal uses from official product information.", "Check a material lot's certificate of analysis against its specification." ], "must_not": [ "Recommend it or a dose for a particular person's asthma or rhinitis.", "Present a maintenance inhaler as a rescue treatment for an asthma attack.", "Supply it outside lawful pharmaceutical channels." ], "requires_human": [ "Any decision to start, stop or change asthma treatment.", "Releasing or destroying a material lot." ] }, "ethics": { "considerations": [ "Asthma attacks can kill; confusion between maintenance and rescue treatment is dangerous.", "Steroid use in children raises concerns that need honest information." ], "affected_parties": [ "People with asthma or rhinitis", "Children and parents", "Prescribers and pharmacists" ] }, "owners": { "steward": "The marketing authorization holder for each medicine; the national medicines regulator oversees it.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity rests on the label, batch record and certificate of analysis, not appearance.", "Supplied in inhalers or nasal sprays named on the device." ], "failure_modes_and_hazards": [ "Using it in place of rescue medication during an attack.", "Local effects such as oral thrush or nosebleeds.", "Growth effects in children with long-term high use." ], "standards_and_regulation": [ "ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation." ], "what_it_is_for": [ "Flunisolide is encountered in pharmaceutical manufacturing, quality control and corticosteroid research.", "It is used in inhaled preparations for asthma maintenance and intranasal preparations for allergic rhinitis.", "Material assessment considers chemical identity, purity and the requirements of the intended formulation." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q3746835: flunisolide", "url": "https://www.wikidata.org/wiki/Q3746835", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Flunisolide", "url": "https://en.wikipedia.org/wiki/Flunisolide", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "flunisolide-identity", "name": "Flunisolide identity", "description": "Establish which chemical entity a name, identifier or material sample denotes.", "rationale": "Flunisolide must be recognised through its specific structure and stereochemistry, not merely its steroid class or commercial name.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Test correspondence with the reference flunisolide molecule.", "findings": [ { "id": "stereostructure-match", "name": "Stereostructure match", "description": "Record evidence that distinguishes the specified fluorinated steroid acetal from related structures.", "questions": [ { "text": "Which authoritative stereostructure defines flunisolide for this record?", "kind": "definition", "id": "stereostructure-match-q01" }, { "text": "Which analytical results establish identity, and can they detect relevant stereochemical or structural mismatches?", "kind": "measurement", "id": "stereostructure-match-q02" } ] } ] }, { "id": "identifier-and-form-boundaries", "name": "Identifier and form boundaries", "description": "Keep parent identity, material form and commercial naming aligned.", "findings": [ { "id": "identifier-scope", "name": "Identifier scope", "description": "Attach each identifier to its actual chemical scope without creating unsupported registry subdivisions.", "questions": [ { "text": "Do the verified CAS number, PubChem CID and any EC identifier denote the same stereostructure and hydration basis?", "kind": "provenance", "id": "identifier-scope-q01" }, { "text": "Does a supplied name denote flunisolide, a hydrated material, a reference standard or a finished medicine?", "kind": "boundary", "id": "identifier-scope-q02" } ] } ] } ] }, { "id": "flunisolide-lot-quality", "name": "Flunisolide lot quality", "description": "Determine what a material lot contains and whether its quality supports a named use.", "rationale": "A correct substance name does not establish active content, impurity acceptability or pharmaceutical suitability.", "layers": [ { "id": "active-content-basis", "name": "Active content basis", "description": "Reconcile weighed material with measured flunisolide content.", "findings": [ { "id": "assay-and-associated-mass", "name": "Assay and associated mass", "description": "Interpret assay together with water, solvent and reporting basis.", "questions": [ { "text": "What is the measured flunisolide mass fraction, and is it reported as-is, dried or anhydrous?", "kind": "measurement", "id": "assay-and-associated-mass-q01" }, { "text": "What correction is justified when converting the supplied material mass into flunisolide-equivalent mass?", "kind": "action", "id": "assay-and-associated-mass-q02" } ] } ] }, { "id": "related-substances-and-grade", "name": "Related substances and grade", "description": "Assess contaminants and the evidence behind a claimed material grade.", "findings": [ { "id": "use-specific-quality-decision", "name": "Use-specific quality decision", "description": "Connect related-substance results and other purity tests to an explicit specification.", "questions": [ { "text": "Which identified and unidentified impurities were measured, by which methods and at what reporting limits?", "kind": "measurement", "id": "use-specific-quality-decision-q01" }, { "text": "Which current specification and certificate support release of this flunisolide lot for its proposed use?", "kind": "provenance", "id": "use-specific-quality-decision-q02" } ] } ] } ] }, { "id": "flunisolide-physical-state", "name": "Flunisolide physical state", "description": "Characterise the solid and its behaviour in relevant solvents.", "rationale": "Limited aqueous solubility makes material form and solvent conditions consequential for handling and formulation.", "layers": [ { "id": "solid-and-thermal-state", "name": "Solid and thermal state", "description": "Establish the observed solid form and interpret thermal transitions.", "findings": [ { "id": "solid-state-evidence", "name": "Solid-state evidence", "description": "A label describes crystalline material and a melting point near 245 °C; record sample-specific methods and distinguish melting from other thermal events. [DailyMed description](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f39cae46-c68f-47ef-82f3-4fd3dd46c74c)", "questions": [ { "text": "What diffraction, thermal or water-content evidence establishes the form of this flunisolide sample?", "kind": "measurement", "id": "solid-state-evidence-q01" }, { "text": "Does the reported thermal event represent melting, desolvation, decomposition or an unresolved combination?", "kind": "boundary", "id": "solid-state-evidence-q02" } ] } ] }, { "id": "dissolution-and-precipitation", "name": "Dissolution and precipitation", "description": "Evaluate transfer from the solid into a specified liquid environment.", "findings": [ { "id": "conditioned-solubility", "name": "Conditioned solubility", "description": "Flunisolide is described as practically insoluble in water; quantitative decisions require solvent- and condition-specific measurements. [DailyMed description](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f39cae46-c68f-47ef-82f3-4fd3dd46c74c)", "questions": [ { "text": "What equilibrium solubility is measured for the identified material form in the proposed solvent mixture and temperature?", "kind": "measurement", "id": "conditioned-solubility-q01" }, { "text": "What evidence supports a concentration that remains dissolved after dilution or temperature change?", "kind": "action", "id": "conditioned-solubility-q02" } ] } ] } ] }, { "id": "flunisolide-stability-and-handling", "name": "Flunisolide stability and handling", "description": "Judge whether storage and manipulation preserve an acceptable substance lot.", "rationale": "Storage suitability and exposure controls must apply to the actual flunisolide material and operation.", "layers": [ { "id": "condition-over-time", "name": "Condition over time", "description": "Relate storage history to chemical and physical quality.", "findings": [ { "id": "stability-supported-disposition", "name": "Stability-supported disposition", "description": "Use material-specific stability evidence to establish retest decisions and investigate excursions.", "questions": [ { "text": "Which studies establish flunisolide stability under the lot's container, temperature, humidity and light conditions?", "kind": "provenance", "id": "stability-supported-disposition-q01" }, { "text": "After an excursion, which assay, impurity or solid-form results are required before the lot can be released again?", "kind": "action", "id": "stability-supported-disposition-q02" } ] } ] }, { "id": "powder-and-solution-exposure", "name": "Powder and solution exposure", "description": "Assess handling hazards for the concentration, form and operation involved.", "findings": [ { "id": "material-specific-controls", "name": "Material-specific controls", "description": "Record substantiated hazard classifications and exposure controls without deriving bulk-substance safety from a dilute medicine label.", "questions": [ { "text": "Which dated safety data sheet and jurisdiction support the hazard classification of the supplied flunisolide material?", "kind": "provenance", "id": "material-specific-controls-q01" }, { "text": "What containment and disposal requirements apply to the planned weighing, dissolution or transfer operation?", "kind": "action", "id": "material-specific-controls-q02" } ] } ] } ] }, { "id": "flunisolide-use-qualification", "name": "Flunisolide use qualification", "description": "Connect substance evidence to research and pharmaceutical uses without taking ownership of finished-product behaviour.", "rationale": "Flunisolide's identity as an anti-inflammatory corticosteroid does not establish approval or suitability of every preparation containing it.", "layers": [ { "id": "pharmacological-role", "name": "Pharmacological role", "description": "Record the substance's biological role and the limits of transferring evidence between contexts.", "findings": [ { "id": "activity-evidence-boundary", "name": "Activity evidence boundary", "description": "Link pharmacological evidence to the tested material, assay or preparation.", "questions": [ { "text": "Which evidence establishes the flunisolide activity relevant to the proposed experimental or formulation purpose?", "kind": "provenance", "id": "activity-evidence-boundary-q01" }, { "text": "Which conclusions concern intrinsic substance activity, and which depend on route, formulation or exposure?", "kind": "boundary", "id": "activity-evidence-boundary-q02" } ] } ] }, { "id": "substance-to-product-interface", "name": "Substance-to-product interface", "description": "Define the evidence required to transfer a substance lot into a separate product workflow.", "findings": [ { "id": "qualified-use-link", "name": "Qualified use link", "description": "Associate the lot with an intended use and applicable requirements while keeping product strength, delivery and authorisation separate.", "questions": [ { "text": "Which jurisdiction, date and intended use determine the applicable flunisolide substance-quality requirements?", "kind": "provenance", "id": "qualified-use-link-q01" }, { "text": "What additional formulation, delivery and authorisation evidence must the receiving product model establish?", "kind": "boundary", "id": "qualified-use-link-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information, not source-verified research.", "Verify hydrate identity, purity specifications, solubility and thermal properties against the exact material form.", "Check current jurisdiction-specific product authorizations and authoritative safety documentation; no GHS classification or occupational exposure limit is asserted here." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of flunisolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "flunisolide", "note": "Names the active substance rather than a particular branded product or delivery device." }, { "scheme": "CAS Registry Number", "value_or_pattern": "3385-03-3", "note": "Identifier for flunisolide; hydrate forms should be checked separately." }, { "scheme": "Molecular formula", "value_or_pattern": "C24H31FO6", "note": "Formula of the anhydrous molecule; not a unique structural identifier." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of flunisolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Active ingredient in inhaled corticosteroid preparations for maintenance treatment of asthma.", "Active ingredient in intranasal corticosteroid preparations for allergic rhinitis." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of flunisolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of anhydrous flunisolide", "typical_range": "434.50", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of flunisolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Inhaled administration can cause oropharyngeal candidiasis and dysphonia.", "Intranasal administration can cause local irritation and nosebleeds.", "Sufficient systemic exposure can produce glucocorticoid effects, including adrenal suppression.", "Inhaled corticosteroid administration can rarely trigger paradoxical bronchospasm.", "Flunisolide is not a rapid bronchodilator; treating it as a rescue medicine can leave acute bronchospasm untreated." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of flunisolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indications, marketed formulations, delivery devices and product availability depend on jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of flunisolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Fluticasone", "difference": "A chemically distinct glucocorticoid with overlapping respiratory uses; molecular structure and substance identifiers distinguish it from flunisolide." }, { "name": "Budesonide", "difference": "Another glucocorticoid used in respiratory therapy, but it lacks fluorine and has a different molecular structure." }, { "name": "Flunisolide inhalation or nasal-spray product", "difference": "A formulated medicine contains flunisolide together with excipients and a delivery system; the registered substance is the active chemical itself." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of flunisolide this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which CAS and EC identifiers are authoritative for the parent substance and any supplied hydrate forms, and how should conflicting identifier records be reconciled?", "Which current pharmacopoeial monographs establish flunisolide identity, assay, related-substance limits and reference-standard requirements?", "Which solid forms and hydration states are experimentally established, and what quantitative solubility and thermal data apply to each?", "Which degradation pathways, storage conditions and retest periods are supported for bulk flunisolide rather than finished products?", "Which current bulk-substance GHS classifications and occupational exposure limits or control bands apply in the intended jurisdiction?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 27 } }